Aurobindo Pharma USA Receives FTC Approval to Acquire Lannett Company

M&A / JV 22 Jun 2026 · In regulatory review· ✓ Verified

Aurobindo Pharma USA, the US subsidiary of India-listed Aurobindo Pharma Limited, received FTC approval on or before 22 June 2026 to proceed with the acquisition of Lannett Company, Inc., a US-domiciled generic pharmaceuticals manufacturer based in Pennsylvania. Lannett is a mid-sized generic player with a portfolio of solid oral and injectable products. The FTC approval represents completion of US antitrust review under the Hart-Scott-Rodino Act and resolves the principal regulatory hurdle for closing.

Why it mattersFTC approval for a pharma acquisition involving overlapping generic product portfolios signals the acquirer's ability to navigate US antitrust scrutiny; key precedent for structuring divestiture/remedy packages in cross-border pharma M&A where product overlap exists.
Counsel—
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object]

Sources

Open in the live tracker →

Related deals